Skip to content
Screener

Candel Therapeutics, Inc. CADL Q1 2026 earnings

Reported May 14, 2026 · Before market open

EPS-$0.14Beat by $0.08
EPS estimate-$0.22

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.30

Financials

Q1 2026

Income statement

See full
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$358.91M+34.5%
Enterprise value$166.92M-10.1%

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity0×-0.1×
Current ratio28×+23.4×

FAQ

When did Candel Therapeutics, Inc. report Q1 2026 earnings?
Candel Therapeutics, Inc. (CADL) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Candel Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $-0.14 for Q1 2026.
Did Candel Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.22 by $0.08.
Where can I find Candel Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-222892) and the 10-Q periodic report (0001193125-26-222904) directly on SEC EDGAR. The filing index links above go to sec.gov.